Amanote Research
Register
Sign In
Correction: Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib
Oncotarget
- United States
doi 10.18632/oncotarget.26577
Full Text
Open PDF
Abstract
Available in
full text
Categories
Oncology
Date
January 4, 2019
Authors
Bin Zhao
Hong Zhao
Publisher
Impact Journals, LLC
Related search
Incidence and Risk of Hematologic Toxicities in Cancer Patients Treated With Regorafenib
Oncotarget
Oncology
Risk of Severe Hematologic Toxicities in Cancer Patients Treated With PARP Inhibitors: A Meta-Analysis of Randomized Controlled Trials
Drug Design, Development and Therapy
Drug Discovery
Pharmacology
Pharmaceutical Science
Incidence and Risk of Severe Neutropenia in Advanced Cancer Patients Treated With Cetuximab
Drugs in R and D
Pharmacology
Factors Predicting Acute Hematologic Toxicities in Cervical Cancer Treated With Postoperative Intensity-Modulated Radiation Therapy and Concurrent Nedaplatin
International Journal of Radiation Oncology Biology Physics
Oncology
Radiology
Cancer Research
Radiation
Nuclear Medicine
Imaging
Paclitaxel-Carboplatin Chemotherapy Induced Hematologic Toxicities Among Epithelial Ovarian Cancer Patients
Universa Medicina
P3.01-100 Risk of Gastrointestinal and Hepatic Toxicities in Patients With Advanced Non-Small-Cell Lung Cancer Treated With Osimertinib
Journal of Thoracic Oncology
Medicine
Oncology
Respiratory Medicine
Pulmonary
Real-World Treatment Patterns Among Patients With Colorectal Cancer Treated With Trifluridine/Tipiracil and Regorafenib
Clinical Colorectal Cancer
Oncology
Gastroenterology
Incidence and Relative Risk of Peripheral Neuropathy in Cancer Patients Treated With Eribulin: A Meta-Analysis
Oncotarget
Oncology
Real‐World Adherence in Patients With Metastatic Colorectal Cancer Treated With Trifluridine Plus Tipiracil or Regorafenib
Oncologist
Cancer Research
Medicine
Oncology
